

# IT Tech Packaging, Inc.

First Quarter 2022
Financial Results Presentation



## **Safe Harbor Statement**



This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, anticipated revenues from the digital photo paper business segment; the actions and initiatives of current and potential competitors; the Company's ability to introduce new products; the Company's ability to implement the planned capacity expansion of corrugate medium paper; market acceptance of new products; general economic and business conditions; the ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the companies and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

# **Agenda**



- Key Highlights
- Financial & Business Review
- Operational & Business Updates



# **Key Highlights for Q1 2022**



Revenue decreased by 36.1% YoY to \$15.5 million, primarily due to the decrease in sales volume of regular corrugating medium paper ("CMP"), offset printing paper and tissue paper products.

Gross profit down 83.0% YoY to \$0.3 million, primarily due to the decrease in sales volume of regular CMP, offset printing paper and tissue paper products. Overall gross margin down 5.6 percentage points to 2.0%.

Loss from operations was \$3.0 million, compared to loss from operations of \$0.7 million for the same period of last year.


Net loss was \$2.5 million, or loss per share of \$0.03, compared to net loss of \$4.3 million, or loss per share of \$0.12, for the same period of last year.

Earnings before interest, taxes, depreciation and amortization ("EBITDA") was \$1.2 million, compared to EBITDA of negative \$0.07 million for the same period of last year.



#### Revenue






#### Q1 2022

- Revenue decreased by 36.1% YoY to \$15.5 million, due to the decrease in sales volume of regular CMP, offset printing paper and tissue paper products.
- Overall gross margin decreased by 5.6 percentage points YoY to 2.0%.
- Operating loss margin decreased by 16.1 percentage points YoY to 19.1%.

# **Corrugating Medium Paper (CMP)**






#### Q1 2022 CMP (includes both Regular and Light-Weight CMP)

- Revenue: down 27.4% YoY to \$15.0 million, accounted for 97.1% of total revenue.
- Sales volume: down 29.6% YoY to 29,086 tonnes.
- ASP: Regular CMP up 2.9% to \$519/tonne.
- ASP: Light-Weight CMP up 2.7% to \$502/tonne.

# **Offset Printing Paper**






#### **Q1 2022 Offset Printing Paper**

- Revenue: was \$nil.
- Sales volume: was \$nil.
- ASP: was \$nil.

# **Tissue Paper**






#### Q1 2022 Tissue Paper

- Revenue: down 68.2% YoY to \$0.4 million, accounted for 2.6% of total revenue.
- Sales volume: down 64.6% YoY to 397 tonnes.
- ASP: down 10.2% YoY to \$1,003/tonne.

#### **Face Mask**







#### Sales Volume and Selling Price (\$) Per Thousand




#### Q1 2022 Face Mask

- Revenue: down 56.6% YoY to \$0.06 million, accounted for 0.4% of total revenue.
- Sales volume: down 21.4% YoY to 3,014 thousand pieces.
- ASP: down 44.1% YoY to \$19/ thousand pieces.

# **Revenue Mix**







<sup>•</sup>Corrugating Medium Paper includes both Light-Weight CMP and Regular CMP

### **Cash Flow**







#### Q1 2022

- Cash position at \$15.4 million as of March 31, 2022.
- Net cash provided by operating activities was \$4.4 million for the first quarter of 2022, as compared to net cash used in operating activities of \$8.3 million for the same period of last year.

# **OPERATIONAL & BUSINESS UPDATES**

# **Tissue Paper Project Progress Update**

– On Site Photos (Taken in April, 2019)











Planned Capacity	30K tonnes/year
Recent Progress	On May 5, 2020, the Company announced it planned the commercial launch of a new tissue paper production line (the "PM10"). The Company has signed an agreement to purchase paper machine with paper machine supplier and expects to launch commercial production of the PM10 following the success of its trial run.





# **Production Facilities of IT Tech Packaging**



PM#	Paper Product	Designed Capacity (tonnes/year)	Location	
PM1	Corrugating medium paper	60,000	Xushui District, Baoding city, Hebei	
PM2	Offset printing paper	50,000	province	
PM3	Offset printing paper	40,000		
PM4 <sup>[a]</sup>	Digital photo paper	2,500	Xushui District, Baoding city, Hebei	
PM5 <sup>[a]</sup>	Digital photo paper	2,500	province	
PM6 <sup>[b]</sup>	Corrugating medium paper	360,000	Xushui District, Baoding city, Hebei province	
PM7	Specialty paper	10,000		
PM8 <sup>(c)</sup>	Tissue paper	15,000	Economic Development Zone in Wei	
PM9 <sup>(d]</sup>	Tissue paper	15,000	County, Hebei Province	
PM10 <sup>[e]</sup>	Tissue Paper	20,000		

[a]: PM4 and PM5 have been suspended in June 2016 due to low market demand

[b]: 23.04% utilization rate in Q1 FY2022; vs. 38.42% in Q1 FY2021.

[c]: The production and sales of tissue paper products have increased steadily since year 2019.

[d]: In November 2019, we completed the commercial launch of a new tissue paper production line the PM9 following the success of its trial production.

[e] In May 2020, we planned commercial launch of a new tissue paper production line PM10 and the Company expects the new tissue paper production line to be launched after the success of its trial run.

# **Income Statement Summary**



	For the Three Months Ended March 31		YoY Change
(US\$)	2022	2021	
Revenue	15,481,618	24,209,427	-36.1%
Cost of sales	(15,171,173)	(22,378,422)	-32.2%
Gross Profit	310,445	1,831,005	-83.0%
Gross profit margin	2.0%	7.6%	5.6pp
Selling, general and administrative expenses	(3,300,881)	(2,555,318)	29.2%
Income (Loss) from operations	(2,956,433)	(724,313)	-308.2%
Operating margin	-19.1%	-3.0%	-16.1pp
Net Income (Loss)	(2,488,214)	(4,338,856)	42.7%
Net (loss) margin	-16.1%	-17.9%	1.8pp
Loss per share – basic and diluted	(0.03)	(0.12)	75.0%

# **Selected Balance Sheet Items**



(US\$)	March 31, 2022	December 31, 2021
Current Assets		
Cash and cash equivalents	15,358,443	11,201,612
Restricted cash	-	-
Accounts receivable	4,984,738	4,868,934
Inventories	4,354,676	5,844,895
Other current assets	23,917,932	33,600,708
Total current assets	48,615,789	55,516,149
Property, plant, and equipment	174,077,916	126,587,428
Other non-current assets	16,317,783	59,431,625
Total Assets	239,011,488	241,535,202
Current Liabilities		
Short-term bank loans	5,984,374	5,958,561
Current portion of long-term loans from credit union	6,868,089	6,838,465
Lease Liability	228,051	210,161
Accounts Payable	72,616	10,255
Other current liabilities	6,785,217	7,416,910
Total current liabilities	19,938,347	20,434,352
Loans from credit union	2,992,974	2,980,065
Deferred gain on sale-leaseback	131,185	155,110
Lease Liability non-current	84,204	152,233
Derivative liability	1,676,946	2,063,534
Total Liabilities	24,823,656	25,785,294
Total Stockholders' equity	214,187,832	215,749,908
Total Liabilities and Stockholders' Equity	239,011,488	241,535,202

# **Solid Operating Cash Flows to Support Continued Investment**



(US\$)	Three Months Ended March 31,	
	2022	2021
Net Cash Provided by (Used in) Operating Activities	4,411,418	(8,280,332)
Net Cash Provided by (Used in) Investing Activities	(7,175,972)	(44,599)
Net Cash Provided by( Used in) Financing Activities	6,893,314	41,794,323
Effect of Exchange Rate Changes on Cash and Cash Equivalents	28,071	(170,838)
Net (Decrease)/Increase in Cash and Cash Equivalents	4,156,831	33,298,554
Cash and Cash Equivalents – Beginning of Period	11,201,612	4,142,437
Cash and Cash Equivalents – End of Period	15,358,443	37,440,991